Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

Ryo Izumi; Toru Hashimoto; Hiroshi Kisanuki; Kei Ikuta; Wataru Otsuru; Soshun Asakawa; Shoei Yamamoto; Kayo Misumi; Takeo Fujino; Keisuke Shinohara; Shouji Matsushima; Kazuya Hosokawa; Shunsuke Katsuki; Taro Mori; Mikiko Hashisako; Yuki Tateishi; Takeshi Iwasaki; Yoshinao Oda; Shintaro Kinugawa; Kohtaro Abe

doi:10.1186/s40959-024-00288-0

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

Ryo Izumi, Toru Hashimoto, Hiroshi Kisanuki, Kei Ikuta, Wataru Otsuru, Soshun Asakawa, Shoei Yamamoto, Kayo Misumi, Takeo Fujino, Keisuke Shinohara, Shouji Matsushima, Kazuya Hosokawa, Shunsuke Katsuki, Taro Mori, Mikiko Hashisako, Yuki Tateishi, Takeshi Iwasaki, Yoshinao Oda, Shintaro Kinugawa, Kohtaro Abe

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.

Original language	English
Article number	82
Journal	Cardio-Oncology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s40959-024-00288-0
Publication status	Published - Dec 2024

All Science Journal Classification (ASJC) codes

Oncology
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s40959-024-00288-0

Cite this

Izumi, R., Hashimoto, T., Kisanuki, H., Ikuta, K., Otsuru, W., Asakawa, S., Yamamoto, S., Misumi, K., Fujino, T., Shinohara, K., Matsushima, S., Hosokawa, K., Katsuki, S., Mori, T., Hashisako, M., Tateishi, Y., Iwasaki, T., Oda, Y., Kinugawa, S., & Abe, K. (2024). Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis. Cardio-Oncology, 10(1), Article 82. https://doi.org/10.1186/s40959-024-00288-0

Izumi, R, Hashimoto, T, Kisanuki, H, Ikuta, K, Otsuru, W, Asakawa, S, Yamamoto, S, Misumi, K, Fujino, T , Shinohara, K , Matsushima, S , Hosokawa, K , Katsuki, S , Mori, T , Hashisako, M , Tateishi, Y , Iwasaki, T , Oda, Y, Kinugawa, S & Abe, K 2024, 'Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis', Cardio-Oncology, vol. 10, no. 1, 82. https://doi.org/10.1186/s40959-024-00288-0

@article{a199c2792dd84585bee2aa093aebaab0,

title = "Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis",

abstract = "The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.",

keywords = "Cardiogenic shock, Fulminant myocarditis, Immune checkpoint inhibitors, Immune-related adverse events, Mechanical circulatory support, Ventricular arrhythmia",

author = "Ryo Izumi and Toru Hashimoto and Hiroshi Kisanuki and Kei Ikuta and Wataru Otsuru and Soshun Asakawa and Shoei Yamamoto and Kayo Misumi and Takeo Fujino and Keisuke Shinohara and Shouji Matsushima and Kazuya Hosokawa and Shunsuke Katsuki and Taro Mori and Mikiko Hashisako and Yuki Tateishi and Takeshi Iwasaki and Yoshinao Oda and Shintaro Kinugawa and Kohtaro Abe",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1186/s40959-024-00288-0",

language = "English",

volume = "10",

journal = "Cardio-Oncology",

issn = "2057-3804",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

AU - Izumi, Ryo

AU - Hashimoto, Toru

AU - Kisanuki, Hiroshi

AU - Ikuta, Kei

AU - Otsuru, Wataru

AU - Asakawa, Soshun

AU - Yamamoto, Shoei

AU - Misumi, Kayo

AU - Fujino, Takeo

AU - Shinohara, Keisuke

AU - Matsushima, Shouji

AU - Hosokawa, Kazuya

AU - Katsuki, Shunsuke

AU - Mori, Taro

AU - Hashisako, Mikiko

AU - Tateishi, Yuki

AU - Iwasaki, Takeshi

AU - Oda, Yoshinao

AU - Kinugawa, Shintaro

AU - Abe, Kohtaro

PY - 2024/12

Y1 - 2024/12

N2 - The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.

AB - The advent of immune checkpoint inhibitors (ICIs) has significantly improved cancer treatment. With the increasing use of ICIs, ICI-related myocarditis has been recognized. However, an evidence-based therapeutic strategy has not been established because of the limited knowledge on ICI-related myocarditis. Here, we present four cases of ICI-related fulminant myocarditis (FM). Three of the four cases resulted in fatal outcomes despite aggressive treatment with mechanical circulatory support and immunosuppressive therapy with corticosteroids. Given the poor prognosis of ICI-FM, the establishment of rapid and adequate therapeutic interventions on the basis of clinical and pathological evaluation is imperative.

KW - Cardiogenic shock

KW - Fulminant myocarditis

KW - Immune checkpoint inhibitors

KW - Immune-related adverse events

KW - Mechanical circulatory support

KW - Ventricular arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=85209722019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85209722019&partnerID=8YFLogxK

U2 - 10.1186/s40959-024-00288-0

DO - 10.1186/s40959-024-00288-0

M3 - Article

AN - SCOPUS:85209722019

SN - 2057-3804

VL - 10

JO - Cardio-Oncology

JF - Cardio-Oncology

IS - 1

M1 - 82

ER -

Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this